Research compounds
Amamelin
Amylin/Calcitonin Dual Agonist
A next-generation dual agonist targeting both amylin and calcitonin receptors. Represents the newest wave of appetite-regulating peptides being explored for weight management.
- Status
- Amamelin is in Phase 1 clinical trials and not approved.
- Evidence
- Preclinical. Evidence comes from animal or lab studies; effects in people are not established.
- Half-life
- Under investigation
- How it's taken
- Subcutaneous injection (investigational)
- Mechanism
- Other
How Amamelin works
Activates both amylin receptors (which signal fullness after meals) and calcitonin receptors (which regulate calcium and may influence appetite). This dual mechanism may provide stronger appetite suppression than single-target approaches.
What research has looked at
- Novel dual mechanism of action
- Strong appetite suppression in early data
- Targets pathways complementary to GLP-1
- Potential for combination therapy
Evidence level: Preclinical. Evidence comes from animal or lab studies; effects in people are not established. These are areas studied or reported, not promised effects.
Reported side effects and risks
- Very early stage — side effect profile not established
- Nausea expected (common with amylin analogs)
- Limited human data
- Safety profile still being characterized
Sources
- Active clinical trials for amylin calcitonin dual agonist · U.S. National Library of Medicine
- PubMed research on dual amylin calcitonin receptor agonist · NIH · National Library of Medicine
- DrugBank record for amylin analog · DrugBank
Track Amamelin in Peptide Vault
Log every dose, set reminders on your own schedule, rotate injection sites and keep your vials organized. Peptide Vault records what you enter. It doesn't recommend compounds or doses. iPhone, on-device.
Related compounds
Amamelin FAQ
What is Amamelin?
A next-generation dual agonist targeting both amylin and calcitonin receptors. Represents the newest wave of appetite-regulating peptides being explored for weight management.
How does Amamelin work?
Activates both amylin receptors (which signal fullness after meals) and calcitonin receptors (which regulate calcium and may influence appetite). This dual mechanism may provide stronger appetite suppression than single-target approaches.
Is Amamelin FDA approved?
No. Amamelin is in Phase 1 clinical trials and not approved. Evidence level: preclinical. Evidence comes from animal or lab studies; effects in people are not established.
What is the half-life of Amamelin?
Reported half-life: Under investigation.
How is Amamelin taken?
Subcutaneous injection (investigational).
What side effects have been reported with Amamelin?
Reported in the sources: Very early stage — side effect profile not established; Nausea expected (common with amylin analogs); Limited human data; Safety profile still being characterized.
Educational summary compiled from the sources listed above. Not medical advice. Peptide Vault does not sell, source or recommend any compound. Talk to a qualified clinician before starting or changing anything.